アケビラ・セラピューティクスのニュース一覧

Investors in Akebia Therapeutics (NASDAQ:AKBA) Have Unfortunately Lost 73% Over the Last Five Years

Yahoo Finance12/20 20:27

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire12/04 05:05

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo (Vadadustat) for CKD Patients on Dialysis

PR Newswire12/03 20:00

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

PR Newswire11/25 21:00

Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...

Benzinga11/14 21:26

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

PRNewswire11/14 21:00

パイパー・サンドラーはアケビラ・セラピューティクス(AKBA.US)のレーティングを強気に据え置き、目標株価を4ドルに据え置いた

パイパー・サンドラーのアナリストAllison Bratzelは$Akebia Therapeutics(AKBA.US)$のレーティングを強気に据え置き、目標株価を4ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は72.3%、平均リターンは28.0%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情

Futuニュース11/14 20:34

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Yahoo Finance11/09 21:33

Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript Summary

Futuニュース11/08 03:02

Akebia Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results.

Benzinga11/07 21:54

Akebia GAAP EPS of -$0.10, Revenue of $37.4M

Seeking Alpha11/07 20:20

アケビラ・セラピューティクス | 10-Q：Q3 2024 四半期報告書

SEC11/07 20:18

Earnings Flash (AKBA) AKEBIA THERAPEUTICS Reports Q3 Revenue $37.4M

MT Newswires11/07 20:13

アケビラ・セラピューティクス | 8-K：Akebia Therapeuticsが2024年第3四半期の決算と最近の業績ハイライトを報告します

SEC11/07 20:08

Akebia Therapeutics 3Q Loss $20M >AKBA

Dow Jones11/07 20:00

Here's the Major Earnings Before the Open Tomorrow

Seeking Alpha11/07 07:00

Press Release: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones11/02 04:05

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire11/01 20:00

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Shares Bounce 29% But Its Business Still Trails The Industry

Simply Wall St10/30 19:09

Market Sentiment Around Loss-Making Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Simply Wall St10/23 19:48